PCSK9: A new participant in lipophagy in regulating atherosclerosis?

被引：10
|
作者：
Xiao, Jun [1 ]
Deng, Yi-Min [1 ]
Liu, Xiang-Rui [1 ]
Cao, Jian-Ping [2 ]
Zhou, Min [1 ]
Tang, Ya-Ling [1 ]
Xiong, Wen-Hao [1 ]
Jiang, Zhi-Sheng [1 ]
Tang, Zhi-Han [1 ]
Liu, Lu-Shan [1 ]
机构：
[1] Univ South China, Hunan Int Sci & Technol Cooperat Base Arterioscle, Key Lab Arteriosclerol Hunan Prov, Inst Cardiovasc Dis, Hengyang 421001, Hunan, Peoples R China
[2] Hunan Environm Biol Vocat & Tech Coll, Hengyang 421001, Hunan, Peoples R China
来源：
CLINICA CHIMICA ACTA | 2019年 / 495卷
基金：
中国国家自然科学基金;
关键词：
Proprotein convertase subtilisin kexin 9; Lipophagy; Lipid metabolism; Low density lipoprotein receptor; Atherosclerosis; SUBTILISIN/KEXIN TYPE 9; LIPID DROPLETS; ENDOPLASMIC-RETICULUM; INCREASED EXPRESSION; APOLIPOPROTEIN-B; RAB7; EFFECTOR; LIVER-DISEASE; AUTOPHAGY; PROTEIN; DEGRADATION;
D O I：
10.1016/j.cca.2019.05.005
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
Proprotein convertase subtilisin kexin 9 (PCSK9) regulates lipid metabolism by degrading low-density lipoprotein receptor on the surface of hepatocytes. PCSK9-mediated lipid degradation is associated with lipophagy. Lipophagy is a process by which autophagosomes selectively sequester lipid-droplet-stored lipids and are delivered to lysosomes for degradation. Lipophagy was first discovered in hepatocytes, and its occurrence provides important fundamental insights into how lipid metabolism regulates cellular physiology and pathophysiology. Furthermore, PCSK9 may regulate lipid levels by affecting lipophagy. This review will discuss recent advances by which PCSK9 mediates lipid degradation via the lipophagy pathway and present lipophagy as a potential therapeutic target for atherosclerosis.
引用
收藏
页码：358 / 364
页数：7
相关论文
共 50 条
  • [1] PCSK9: A emerging participant in heart failure
    Xu, Qian
    Zhao, Yi-meng
    He, Nai-qi
    Gao, Rong
    Xu, Wen-xin
    Zhuo, Xiu-juan
    Ren, Zhong
    Wu, Chun-yan
    Liu, Lu-shan
    BIOMEDICINE & PHARMACOTHERAPY, 2023, 158
  • [2] PCSK9 IN THE DEVELOPMENT OF HUMAN ATHEROSCLEROSIS
    Abou-Khalil, Y.
    Azar, Y.
    Elbitar, S.
    Lebel, M. -N.
    Deschildre, C.
    Ghaleb, Y.
    Dupont, S.
    Guillas, I.
    Le Goff, W.
    Le Goff, C.
    Boileau, C.
    Varret, M.
    Fadel, M. Abi
    Michel, J. B.
    El Khoury, P.
    ATHEROSCLEROSIS, 2021, 331 : E66 - E66
  • [3] An Update on the Role of PCSK9 in Atherosclerosis
    Yurtseven, Ece
    Ural, Dilek
    Baysal, Kemal
    Tokgozoglu, Lale
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2020, 27 (09) : 909 - 918
  • [4] PCSK9 as a Therapeutic Target in Atherosclerosis
    Ali J. Marian
    Current Atherosclerosis Reports, 2010, 12 (3) : 151 - 154
  • [5] PCSK9 and Atherosclerosis - Lipids and Beyond
    Shapiro, Michael D.
    Fazio, Sergio
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2017, 24 (05) : 462 - 472
  • [6] PCSK9 and atherosclerosis: beyond LDL
    Catapano, A. L.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2017, 47 : 28 - 28
  • [7] Role Of Retinoid X Receptor In Regulating Pcsk9 Transcription In The Liver And Atherosclerosis
    Choubey, Mayank
    Wang, Xiang
    Tirumalasetty, Munichandra
    Yadav, Pradeep K.
    Ansari, Abulaish
    Rajan, Sujith
    Hu, Wenquan
    Hussain, M. M.
    Miao, Qing R.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2023, 43
  • [8] New developments in atherosclerosis: clinical potential of PCSK9 inhibition
    Giunzioni, Llaria
    Tavori, Hagai
    VASCULAR HEALTH AND RISK MANAGEMENT, 2015, 11 : 493 - 501
  • [9] Role of PCSK9 in lipid metabolism and atherosclerosis
    Lin, Xiao-Long
    Xiao, Le-Le
    Tang, Zhi-Han
    Jiang, Zhi-Sheng
    Liu, Mi-Hua
    BIOMEDICINE & PHARMACOTHERAPY, 2018, 104 : 36 - 44
  • [10] PCSK9: A key factor modulating atherosclerosis
    Li, Sha
    Li, Jian-Jun
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2015, 22 (03) : 221 - 230
12345